{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Premafloxacin is an 8-methoxy fluoroquinolone derivative patented by American pharmaceutical company Warner-Lambert Co. as an antibacterial agent. In preclinical studied. Premafloxacin was equivalent to ciprofloxacin, enrofloxacin, and danofloxacin in activity against the gram-negative bacilli but was much more active than the comparison antimicrobial agents (against the staphylococci, streptococci, and anaerobes. Premafloxacin acts as a topoisomerase IV inhibitor with enhanced activity against Staphylococcus aureus.
Status:
Investigational
Source:
NCT01459926: Phase 2 Interventional Completed Opioid Induced Constipation
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Axelopran (previously known as TD-1211), a peripherally selective, multivalent µ-opioid receptor antagonist that is under development by Theravance Biopharma. This drug participated in phase II clinical trials in subjects with opioid-induced constipation. The most common adverse events were abdominal pain, nausea, and diarrhea. There were no indications of opioid withdrawal effects or reductions in opioid analgesia in patients treated with axelopran.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Luminespib (NVP-AUY922) is a highly potent isoxazole-based, nongeldanamycin HSP90 inhibitor that inhibits the adenosine triphosphatase activity of
HSP90. Luminespib is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib potently inhibited in vitro growth in all 41 NSCLC cell lines evaluated with IC50 less than 100 nM. IC100 value less than 40 nM was seen in 36 of 41 lines. Luminespib (NVP-AUY922) has greater potency, reduced hepatotoxicity, and lower dependence on DT-diaphorase than the first-generation HSP90 inhibitors. Luminespib was discovered in a multiparameter lead optimization program based on a high-throughput screening hit methodology developed jointly by The Institute of Cancer Research, UK and the pharmaceutical company Vernalis. It has been licensed to Novartis. Luminespib activity is independent of NQO1/DT-diaphorase, maintained in drug-resistant cells and under hypoxic conditions. The molecular signature of HSP90 inhibition, comprising induced HSP72 and depleted client proteins, was readily demonstrable. Pre-clinical studies proved that Luminespib acts via several processes (cytostasis, apoptosis, invasion, and angiogenesis) to inhibit tumor growth and metastasis. These results helped Luminespib to enter clinical trials for various cancers including breast cancers. From 2011 to 2014 it was in Phase II clinical trials.
Status:
Investigational
Source:
NCT04525391: Phase 2 Interventional Terminated SCLC, Recurrent
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
AstraZeneca and BIND Therapeutics (formerly BIND Biosciences) are collaborating to develop AZD-1152HQPA (AZD2811) for the treatment of cancer. AZD2811, a novel, selective inhibitor of Aurora B kinase that has been shown to be active in both solid and hematological tumors in preclinical models, is the second Accurin candidate to enter clinical development. AZD1152-HQPA is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay. AZD1152-HQPA inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM. The phase 1 trial is enrolling patients with advanced solid tumors, including patients with small cell lung cancer, and is being conducted by AstraZeneca under the companies’ 2013 collaboration agreement with BIND managing all chemistry, manufacturing and control activities.
Status:
Investigational
Source:
NCT02928211: Phase 1 Interventional Unknown status Mild Cognitive Impairment
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Aftobetin, also known as ANCA11 and NCE-11, is a novel amyloid–binding compound applied topically in the form of an ophthalmic ointment. Aftobetin offers a promising way for a noninvasive eye-scan to diagnose Alzheimer’s disease early.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Stilbazium is a pyridinium derivative with considerable anthelminthic activity against some animal nematodes, including Syphacia obvelata, Ancylostoma caninum, Uncinaria stenocephala and Toxocara cati.
Status:
Investigational
Source:
INN:locnartecan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02457273: Phase 2 Interventional Completed Neuroendocrine Carcinomas
(2015)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT04316143: Phase 2 Interventional Completed Pulmonary Arterial Hypertension
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zamicastat (also known as BIA 5-1058) is a dopamine β-hydroxylase (DβH) inhibitor that decreases noradrenaline and increases dopamine levels in peripheral sympathetically innervated tissues. It is known that the use of DβH inhibitors is a promising approach to treat hypertension, heart failure and cardiovascular diseases where a reduction in the sympathetic tone has beneficial effects. Zamicastat participated in phase II clinical trials in pulmonary arterial hypertension as adjuvant therapy in Austria. In addition, the drug successfully completed phase I in patients with hypertension and chronic heart failure.
Status:
Investigational
Source:
JAN:DL-METHYLEPHEDRINE SACCHARINATE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
